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Background: Nasopharyngeal carcinoma (NPC) has a high incidence rate in Southern China. Although there are
conventional therapies, the side effects and toxicities are not always tolerable for patients. Recently, the tumoricidal
effect of ginsenosides on different cancer cells has been studied. This study aims to investigate the anti-cancer
effect of ginsenosides on NPC cells and their underlying mechanism.
Methods: The cytotoxicity of ginsenosides on NPC cell line HK-1 was measured by MTT assay. Apoptosis was
detected by propidium iodide staining followed by flow cytometry. A xenograft tumor model was established by
injecting nude mice with HK-1 cells. The activation of caspases and apoptosis-inducing factor (AIF) were evaluated
by Western blot analysis. Nuclear translocation of AIF was also studied by immunofluorescence staining. Mitochondrial
membrane potential was measured by JC-1 dye using flow cytometry.
Results: Four ginsenosides, 20 (S)-Rh2, compound K (CK), panaxadiol (PD) and protopanaxadiol (PPD), induced
apoptotic cell death in HK-1 cells in a concentration-dependent manner. CK inhibited HK-1 xenograft tumor growth
most extensively and depleted mitochondrial membrane potential depolarization and induced translocation of AIF
from cytoplasm to nucleus in HK-1 cells. In addition, depletion of AIF by siRNA abolished CK-induced HK-1 cell death.
Conclusion: Ginsenoside CK-induced apoptosis of HK-1 cells was mediated by the mitochondrial pathway and could
significantly inhibit tumor growth in vivo.Background
Nasopharyngeal carcinoma (NPC) is a head and neck
cancer with a distinctive ethnic and geographic distribu-
tion. In Southern China, NPC has a high incidence of
about 25–30 per 100,000 persons per year, in contrast to
the low incidence of less than 1 per 100,000 persons per
year was recorded in Western countries [1]. The common
treatment for NPC is radiotherapy. Besides the undesir-
able side effects of radiotherapy, the location of the tumor
also leads to complications after treatment. Chemotherapy
is an alternative in treating NPC but resistance to con-
ventional drugs is a challenge. Therefore, new multiple
regimens such as radiochemotherapy and combination
treatments with adjuvant drugs are being studied [2].* Correspondence: patrick@hkbu.edu.hk; rnswong@hkbu.edu.hk
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reproduction in any medium, provided the orGinsenosides are a group of saponin glycosides, which
contribute to the pharmacological effects of ginseng [3].
More than 40 ginsenosides have been separated and iden-
tified from ginseng [4,5] and can be classified into three
groups: protopanaxadiols (PPD) (e.g., Rb2, Rc, Rd, Rg3,
and Rh2), protopanaxatriols (PPT) (e.g., Re, Rf, Rg1, Rg2,
and Rh1), and oleanolic acid derivatives [6,7]. Structure-
activity relationship studies on different ginsenosides and
their anti-cancer effects have been demonstrated that gin-
senosides with a sugar moiety at C-6 (PPT-type) exhibit
less cytotoxicity than those without a sugar moiety at C-6
(PPD-type) [8]. In the last few years, ginsenosides were re-
ported to be responsible for the vasorelaxation, antioxida-
tion, anti-inflammation, anti-angiogenesis and anti-cancer
effects of ginseng [9,10]. Ginsenosides PPD and Rh2 ex-
hibited anti-proliferative effects on intestinal and glioma
cell models [11-13]. Apoptosis induction by different gin-
senosides was also demonstrated on human astrocytoma. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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HT-29 colon cells [14-18]. Compound K (CK) is the
major metabolite of PPD-type ginsenosides, and is
transformed by intestinal bacteria [19]. CK is rapidly
absorbed in the gastrointestinal tract and is retained for
a long time in rat plasma [20,21]. The anti-angiogenic
effect of CK was also reported [14,16,22]. Although the
anti-cancer effects of ginsenosides have been studied ex-
tensively in other cancer models, the effect of ginseno-
sides on NPC is unknown. Several natural compounds
extracted from plants could induce apoptosis in NPC
through the mitochondria-dependent pathway. For ex-
ample, capsaicin (EC50 ~ 300 μM) from hot chili peppers
[23], aloe emodin (EC50 100 μM) [24], and rhein (EC50
180 μM) [25] isolated from the rhizome of rhubarb, in-
duced depletion of mitochondrial membrane potential
and subsequent AIF release in NPC-derived cell lines.
However, ginsenosides and especially CK are more potent
(EC50 15 μM) than these natural compounds. Although
caspase-dependent apoptosis induced by CK was reported
in other cancer cell-lines [26-28], cell type-specific intra-
cellular signaling might account for the discrepancy ob-
served. The adjuvant effect of ginsenosides has been
demonstrated by increasing chemotherapy efficacy [15]
and patient survival rates [29,30].
This study aims to investigate the anti-cancer effects
and action mechanism of ginsenosides on NPC cells.
Methods
Ginsenosides
High-performance liquid chromatography-purified ginse-
nosides as standard compounds (purity >98%) were pur-
chased from Fleton Natural Products (Chengdu, China).
Stock solutions of PPD (20 mM), CK (40 mM), and 20
(S)-Rh2 (40 mM) were prepared in dimethyl sulfoxide
(DMSO) (Sigma Aldrich, St. Louise, MO, USA), while PD
(20 mM) was prepared in absolute ethanol.
Cell culture and drug treatments
NPC cell line HK-1 was maintained in RPMI 1640 medium
(Gibco, Grand Island , NY, USA) supplemented with 10%
fetal bovine serum (FBS) (Gibco) and 1% penicillin and
streptomycin (Gibco) at 37°C in a humidified incubator
with 5% CO2. HK-1 cells were starved in medium with 1%
FBS for 24 h before drug treatment. Cells were treated
with indicated concentrations of ginsenosides for different
times in medium supplemented with 1% FBS.
Cell viability assay
Cell viability was determined by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Briefly,
HK-1 cells (1 × 104 cells/well) were seeded onto 96-well
plates and incubated overnight. Cells were starved in
medium with 1% FBS for 24 h and then subjected todifferent treatments for another 24 h. After that, MTT so-
lution (USB, Cleveland, OH, USA) was added into each
well to a final concentration of 0.5 mg/mL and incubated
for 3 h. The culture medium was then removed and
DMSO was added to solubilize the purple formazan prod-
uct. Absorbances at wavelengths of 540 and 690 nm were
measured by a microplate reader (ELx800, Biotek, Winoo-
ski, VT, USA).
Cell cycle analysis
HK-1 cells (1.5 × 105 cells/well) were seeded onto 6-well
plates and incubated overnight. Cells were starved in
medium with 1% FBS for 24 h and then treated with dif-
ferent ginsenosides for 24 h. Cells were harvested,
washed with PBS (Gibco) twice, and fixed in 70% etha-
nol at −20°C. The cells were then stained with propi-
dium iodide solution (Sigma-Aldrich) containing RNase
A (1 mg/mL) (Roche, Mannheim, Germany). Cell-cycle
analysis was performed with the FACSCalibur Flow Cyt-
ometer (BD Biosciences, San Jose, CA, USA) and the
data were analyzed with the Cell Quest and the Modfit
LT Version 3.0 software (Verity Software House, Topsham,
Maine, USA).
Western blot analysis
After drug treatment, cytosolic and nuclear lysates were
extracted with the NE-PER Nuclear Protein Extraction
Kit (Millipore, Bedford, MD, USA) according to the
manufacturer’s protocol. The cytosolic fraction was ex-
tracted with cytoplasmic lysis buffer (1× cytoplasmic
lysis buffer, 0.5 mM DTT, 1:1000 dilution of inhibitor
cocktail) while the nuclear fraction was extracted with
nuclear extraction buffer (1× nuclear extraction buffer,
1:1000 dilution of inhibitor cocktail). Protein concentra-
tions were determined with the Bio-Rad Dc protein
assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts
of protein samples were separated by SDS-PAGE and
transferred onto a nitrocellulose membrane. The mem-
brane was then probed with primary antibodies (anti-AIF)
(Cell Signaling, Beverly, MA, USA) and subsequently in-
cubated with secondary antibodies (HRP-conjugated goat
anti-rabbit IgG) (Invitrogen). After washing with 0.1%
TBS-T (USB), the membrane was visualized by an en-
hanced chemiluminescence detection system (Bio-Rad).
For the cytosolic fraction, protein expression was com-
pared with β-actin (Sigma-Aldrich). For the nuclear
fraction, lamin A/C (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) was used for normalization.
Xenografts in nude mice
Male BALB/c nude mice were purchased from the Animal
Services Centre of Chinese University of Hong Kong. For
the animal study, HK-1 cells were harvested and washed
twice with PBS. For each site of injection, 3 × 106 HK-1
Figure 1 Cytotoxic effect of 20 (S)-Rh2, CK, PD and PPD on
HK-1 cells. Cells were treated with different ginsenosides for 24 h in
1% FBS supplemented RPMI 1640 medium. The cell viability was
determined by MTT assay and expressed as a percentage of solvent
control in each experiment. Results were presented as mean ± SD
from three independent experiments. **P < 0.01 and ***P < 0.001 20
(S)-Rh2 compared to the DMSO control group. #P< 0.05 and ###P< 0.001
CK compared to the DMSO control group. +P < 0.05, ++P < 0.01
and +++P< 0.001 PD compared to the ethanol control group. §P< 0.05
and §§§P < 0.001 PPD compared to the DMSO control group.
Figure 2 Induction of apoptosis on ginsenosides-treated HK-1 cells. H
and PPD (10 μM) for 24 h in 1% FBS RPMI 1640 medium. The cell cycle wa
analysis. The data were analyzed by the Cell Quest and the Modfit LT Versi
cycle phases. Apoptosis was examined by comparing the sub-G1 populatio
histograms of three independent experiments. (B) Statistical analysis on the
mean ± SD from three independent experiments. *P < 0.05 and **P < 0.01 c
ethanol control group.
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culture medium and mixed with Matrigel in a 1:1 ratio
(BD Biosciences). The cell-matrigel mixture was inocu-
lated subcutaneously into the left and right flanks of 6–
7 week-old nude mice. When the tumors were palpable
(8 days after injection), the tumor-bearing animals were
randomly divided into two groups (four mice per group).
In group 1, mice were treated with 10 mg/kg/day CK or-
ally (CK was mixed in a 0.5% carboxymethyl cellulose
[CMC] suspension). In group 2, mice were treated with
0.5% CMC orally as the control. Tumor sizes were mea-
sured daily and calculated using the formula (L ×W2)/
2 mm3 (L = length; W = width). The experiment was
performed according to the Animals (Control of Experi-
ments) Ordinance (Hong Kong) and followed the Hong
Kong Baptist University’s guidelines on animal experi-
mentation. The tumor inhibition (%) was calculated as
follows:
Tumor inhibition (%) = (Tumor volume of control
group − Tumor volume of CK-treated group)/(Tumor
volume of control group).
Detection of mitochondrial membrane potential
HK-1 cells were incubated with 5 μg/mL JC-1 dye (Invi-
trogen) for 30 min. After that, cells were trypsinized andK-1 cells were treated with 20(S)-Rh2 (15 μM), CK (15 μM), PD (10 μM)
s then evaluated by propidium iodide staining and flow cytometric
on 3.0 software to determine the percentage of cells in different cell
n in HK-1 cells treated with or without ginsenosides. (A) Representative
percentage of sub-G0/G1 populations. Results were presented as
ompared to the DMSO control group. #P < 0.05 compared to the
Figure 3 Activation of caspase-3, -8 and -9 after ginsenosides treatment on HK-1 cells. HK-1 cells were treated with ginsenosides (A) 20(S)-
Rh2 (15 μM), (B) CK (15 μM), (C) PD (10 μM) and (D) PPD (10 μM) in 1% FBS supplemented RPMI 1640 medium. Cells lysates were harvested at
indicated time points for Western blot analysis using antibodies against both pro and active forms of caspase-3, -8 and -9. The expression of the
pro and active forms was indicated by solid and hollow arrows, respectively. β-actin was used as a protein loading control.
Figure 4 CK attenuated the HK-1 tumor growth in vivo. (A)
Chemical structure of ginsenoside-CK. (B) The HK-1 xenograft tumor
model was established by injecting 3 × 106 cells subcutaneously to the
left and right flanks of nude mice, respectively. Animals (4 mice per
group) were treated with 10 mg/kg/day CK or 0.5% CMC (as control)
orally for 5 days when tumors were palpable. Tumor sizes were measured
daily. **P < 0.01 and ***P < 0.001 compared to the control group.
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monomers and J-aggregates were detected by a flow cyt-
ometer on the FL1 and FL2 channels, respectively. The
mitochondrial membrane potential is presented by the
580/530 nm ratio.Figure 5 Effect of caspase inhibitors on CK-induced HK-1 cell
death. HK-1 cells were pretreated with or without different
concentrations of caspase cocktail inhibitor (CI) for 2 h followed by
24 h of CK (15 μM) treatment in 1% FBS supplemented RPMI 1640
medium. The cell viability was determined by MTT assay and
expressed in percentage of solvent (DMSO) control. Results were
presented as mean ± SD from three independent experiments.
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HK-1 cells were seeded on a glass coverslip at a density
of 2 × 105 cells/well in a 6-well plate and incubated over-
night. Cells were starved with 1% FBS medium for 24 h
and then treated with or without CK for another 8 and
24 h. The medium was then removed and the glass cover
slips were washed with PBS. After that, cells were fixed
with 4% paraformaldehyde (Sigma Aldrich) for 10 min
followed by washing with PBS three times. Cells were
permeabilized with 0.2% of Triton X-100 for 10 min
followed by washing with PBS. Cells were probed with
anti-AIF antibody in 3% BSA (Sigma Aldrich) overnight at
4°C and then secondary antibody (PE-conjugated goat-
anti-rabbit IgG) (Invitrogen) for 2 h at room temperature.
After washing with PBS, the coverslip was incubated with
DAPI (0.5 g/mL) (Invitrogen) for 5 min. Coverslips were
mounted with fluorescence mounting medium on slides
and were subjected to examination and image capture by
an Olympus FV1000 confocal scanning laser microscope
(Essex, UK).
Transfection of small interference RNA (siRNA)
HK-1 cells were seeded onto 6-well plates overnight,
cells were then transfected with AIFM1 specific siRNAFigure 6 CK-induced HK-1 cell death is dependent on AIF translocatio
supplemented RPMI 1640 medium for 1 day followed by treatment with C
collected and fractionated with nuclear extraction kit into cytosolic and nu
protein expression of AIF, lamin A/C (nuclear marker) and β-actin (cytosolic
translocation of AIF from cytoplasm to nucleus. Cells were stained with ant
staining (blue) was used to show the nuclei. Images were captured by con
AIF. (C) Cytotoxic effect of CK on HK-1 was reduced by AIF siRNA. After tra
serum-free RPMI 1640 medium, cell viability was determined by MTT assay
Results were presented as mean ± SD from three independent experiments
non-targeting siRNA CK group.(50 nM) (Ambion, Austin, TX, USA) using Lipofectamine
RNAiMAX transfection reagent (Invitrogen) in antibiotic-
free RPMI-1640 culture medium. Drug treatment was per-
formed 48 h after transfection.
Statistical analysis
All data were presented as mean ± standard deviation
(S.D). Comparisons were subjected to Student’s t-test or
Kruskal-Wallis One Way Analysis of Variance (ANOVA)
followed by Dunnets post hoc test for multiple compari-
sons. Statistical significance was accepted at P < 0.05.
Results
Ginsenosides 20(S)-Rh2, CK, PD, and PPD exhibited
cytotoxicities towards HK-1 cells
Using the MTT assay, ginsenoside 20(S)-Rh2, CK, PD,
and PPD (1–20 μM) treatment inhibited growth of HK-1
cells in a dose-dependent manner (Figure 1). The IC50 of
20(S)-Rh2, CK, PD, and PPD, on HK-1 cells was 12, 11.5,
8, and 7 μM, respectively. Different concentrations of 20
(S)-Rh2 (15 μM), CK (15 μM), PD (10 μM), and PPD
(10 μM) were selected for subsequent studies. These
data suggested that ginsenosides possess a cytotoxic ef-
fect on HK-1 cells.n from cytoplasm to nucleus. Cells were starved in 1% FBS
K (15 μM) for the indicated time intervals. (A) Cell lysates were
clear fractions. Western blot analysis was used to determine the
maker). (B) Immunostaining of cells was performed to show the
i-AIF antibody and a PE secondary antibody (red) to localize AIF. DAPI
focal laser scanning microscope. Arrows indicate cells with translocated
nsfection of siRNA, HK-1 cells were treated with CK (1 μM) for 24 h in
and expressed as a percentage of solvent control in each experiment.
. **P < 0.01 compared to the DMSO control group, ##P < 0.01 versus
Figure 7 Mitochondrial membrane potential of HK-1 cells after
CK treatment. HK-1 cells were treated with CK (15 μM) for 4
and 24 h. Mitochondrial membrane potential was examined by flow
cytometry with JC-1 probe treatment. Aggregate form of JC-1 was
present in mitochondria with high membrane potential, whereas its
monomeric form appeared in mitochondria with low membrane
potential. The aggregate and monomeric forms of JC-1 were
detected by FL1 and FL2 detectors of flow cytometer, respectively.
(A) Representative flow cytometry scatterplots were shown. The cell
distribution in the Q4 area indicated the cells which had low
mitochondrial membrane potential. (B) Mitochondrial membrane
potential was presented in 580/530 nm ratio. The histogram
showed the relative change of mitochondrial membrane potential
to the control. ***P < 0.001 versus control at 4 h, ##P < 0.01 versus
control at 24 h.
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The sub-G1 phase population represents cells in apoptosis.
As shown in Figure 2A and 2B, ginsenosides 20(S)-Rh2,
CK, PD, and PPD-treated HK-1 cells had a sub-G1 popula-
tion of 4.0, 17.7, 5.6, and 4.6%, respectively. Ginsenosides
can significantly induce apoptotic cell death in HK-1 cells.
Ginsenosides induced caspase activation in HK-1 cells
Caspase-3, -8, and -9 were all activated by selected ginseno-
sides at different time points in HK-1 cells (Figure 3). In the
case of 20(S)-Rh2 (Figure 3A) and CK (Figure 3B), treat-
ment for 8 and 24 h activated the caspase-3, -8, and -9.
In contrast, activation of the caspase cascade by PD
(Figure 3C) and PPD (Figure 3D) occurred around 24 h
after drug treatment. Moreover, earlier and stronger ac-
tivation of caspase-8 was observed in 20(S)-Rh2- and
CK-treated HK-1 cells when compared with PD- and
PPD-treated cells. This implies that 20(S)-Rh2- and CK-
induced apoptotic cell death in HK-1 cells may be medi-
ated through the mitochondrial pathway.
CK attenuated HK-1 xenograft tumors in vivo and induced
caspase-independent apoptosis
Among the four tested ginsenosides, we previously dem-
onstrated the moderate cytotoxic effect of CK towards
HK-1 cells. Additionally, CK induced a relatively high sub-
G1 phase population and early activation of caspase cas-
cade when compared with other ginsenosides. As CK is
the most abundant metabolite of PPD-type ginsenosides,
we selected ginsenoside CK (Figure 4A) as the represen-
tative ginsenoside in our further studies. In the animal
experiment, tumor size in the CK-treated group was
25.6% lower than that in the control group at day 5. The
average size of the eight tumors in the CK-treated group
was 54.2 – 62.2 mm3 vs. 70.6 – 79.8 mm3 in the control
group (Figure 4B). No adverse effects were observed in
either group of animals.
In contrast to the western blot analysis on caspase acti-
vation, pretreatment with caspase inhibitors (Z-D (OMe)
E (Ome) VD (OMe)-FMK, Z-IE (OMe) TD (OMe)-FMK,
and Z-LE (OMe) HD (OMe)-FMK) together at 10, 15,
or 20 μM did not reverse the cell death induced by CK
(Figure 5). This indicates that the caspase activation was
not the major pathway involved in the mechanism of
CK-induced cell death. Thus, the caspase-independent
apoptotic pathway was investigated.
CK induced apoptosis-inducing factor (AIF) translocation
and mitochondrial membrane depolarization
Translocation of AIF from mitochondria to nucleus is the
key event of the caspase-independent apoptotic pathway
[31]. Cells were treated with CK for 1, 4, 8, and 24 h. The
mature form of AIF was significantly increased in both
cytosolic and nuclear fractions after 4, 8, and 24 htreatments (Figure 6A). In addition, AIF translocation into
nucleus was detected by immunofluorescence staining
after 8 and 24 h treatment of CK (Figure 6B). We fur-
ther confirmed that CK-induced apoptosis was dependent
on the activation of AIF, siRNA of AIF was employed
(Additional file 1: Figure S1). The cytotoxic effect of CK
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which demonstrated the crucial role of AIF in CK-induced
HK-1 cell death. Translocation of AIF requires the
opening of mitochondrial pores. Therefore, mitochondrial
membrane potential was determined by flow cytometry.
Depolarization of the mitochondrial membrane potential
was observed as early as 4 h after CK treatment with
the potential decreased by nearly one-fold. Further
depolarization was found after 24 h treatment (Figure 7A
and 7B). This implied that CK-induced cell death in HK-1
cells was mitochondrially mediated.
Discussion
Ginsenosides were reported to exhibit anti-proliferative,
anti-metastatic, and anti-angiogenic activities in different
in vitro and in vivo tumor models [10,32-35]. However,
different ginsenosides induced diverse biological effects
on different models due to structural differences. The
number of sugar moieties were found to mediate ginse-
nosides activity by altering hydrophilicity. Moreover,
aglycone ginsenosides (i.e., CK, PPD, and PPT) showed
higher cytotoxicity than glycosides. This property of gin-
senosides also mediated their affinity towards different
molecular targets. CK is the major metabolite of all
PPD-type ginsenosides in both rat and human plasma
[20,21,31]. Aside from its tumoricidal effects, CK was
shown to have neuroprotective, hypoglycemic, and
antidepressant-like effects in mice, and enhancement
of type I procollagen levels in ultraviolet-A-irradiated
fibroblasts [36-39]. In the present study, HK-1 cellsFigure 8 Schematic diagram of ginsenoside CK-induced caspase-inde
AIF translocation and cleavage of caspases, but the induction of apoptosishad a similar response towards 20(S)-Rh2, CK, PD, and
PPD, and ginsenoside CK showed the most potent sub-
G1 phase induction.
Apoptosis is a common type of cell death induced by
anti-cancer drugs. Ginsenosides can induce apoptosis in
different cancer models including human astrocytoma
cells, HT-29 colon cells, A431 cells, and HeLa cells
[14,17,18,40]. Apoptosis is mainly induced by a caspase
cascade or translocation of AIF [41]. There are two path-
ways of caspase activation, which are the cell surface
death receptor pathway (extrinsic) and mitochondria-
initiated pathway (intrinsic). Caspase-3 is the “execute”
caspase for the apoptotic induction, while caspase-8 and
caspase-9 are the critical caspases and signify the activa-
tion of the extrinsic and intrinsic pathways, respectively
[42]. In our study, we demonstrated apoptosis induction
and caspase activation of ginsenosides in NPC cells. And
pretreatment with caspase inhibitors did not reverse the
cell death of CK-treated cells. This indicated that CK-
induced cell death was caspase-independent. Besides in-
ducing apoptosis, caspase activation was involved in other
cellular responses, such as differentiation or cell migration
[43]. Therefore, the CK-activated caspase cascade did not
participate in the apoptotic execution.
Apart from the caspase-dependent apoptotic pathway,
there is a caspase-independent apoptotic pathway in which
AIF translocates from cytoplasm to nucleus [44,45]. AIF is
a flavoprotein inducing DNA damage, chromatin conden-
sation, and DNA degradation [31,46], which is normally
present in mitochondria and will translocate into nucleuspendent apoptosis on NPC cell. Ginsenoside CK could activate both
was only dependent on AIF activation.
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location of AIF and depolarization of mitochondrial
membrane potential were induced by CK treatment in
HK-1 cells (Figure 8). This implied that CK induced
apoptotic cell death of HK-1 cells via depolarization
of mitochondrial membrane potential and activation
of AIF.
Conclusion
Ginsenoside CK-induced apoptosis of HK-1 cells was me-
diated by the mitochondrial pathway and could signifi-
cantly inhibit tumor growth in vivo.
Additional file
Additional file 1: Figure S1. Confirmation of knockdown of AIF. HK-1
cells were transfected with AIF-specific siRNA for 24 h. Expression of
mature AIF was detected by Western blot analysis. β-actin was used as a
protein loading control.
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